Identifying genetic factors that predict dietary intervention success in IBS
Whole Genome Association Study (GWAS) to Identify Predictive Genetic Factors for the Success of Dietary Intervention in the Treatment of Irritable Bowel Syndrome (IBS) Symptoms
This study is trying to find out if certain genes can help predict how well people with Irritable Bowel Syndrome will respond to a special diet that combines low FODMAP and Mediterranean foods.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Attikon Hospital Academic / other |
| Locations | 1 site (Athens) |
| Trial ID | NCT06912828 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify single nucleotide polymorphisms (SNPs) that may influence the response to a combined dietary intervention consisting of a low FODMAP diet and the Mediterranean diet in patients with Irritable Bowel Syndrome (IBS). Blood samples will be collected for DNA extraction, and genotyping will be performed using Next Generation Sequencing (NGS) technology. The study will also assess symptom severity using the IBS-SSS scale and mental health status with the HADS questionnaire. Participants will be recruited from the Department of Clinical Nutrition at Attikon University General Hospital.
Who should consider this trial
Good fit: Ideal candidates include individuals who meet the Rome IV criteria for IBS and have a symptom severity score greater than 175.
Not a fit: Patients with concomitant diseases requiring specialized nutrition or those who are pregnant or breastfeeding may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized dietary interventions for IBS patients based on their genetic profiles.
How similar studies have performed: While there have been studies exploring dietary interventions for IBS, this specific genetic approach using GWAS is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Fulfillment of the Rome IV criteria for IBS * Provision of written informed consent. * Commitment of availability throughout the study period. * IBS-SSS \> 175 Exclusion Criteria: * Any concomitant disease requiring specialized nutrition (e.g. renal failure, diabetes, celiac disease, cerebrovascular disease of the central nervous system, major surgical cavity). * Pregnancy. * Breastfeeding.
Where this trial is running
Athens
- Attikon General University Hospital of Athens — Athens, Greece (Recruiting)
Study contacts
- Study coordinator: Konstantinos Triantafyllou, Proffesor
- Email: ktriant@med.uoa.gr
- Phone: +306977402690
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.